64th ASH Annual Meeting and Exposition: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Venetoclax, HMA, and Response to Treatment in AML

Symposia: Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Oral and Poster Abstracts
Oral

Research, Acute Myeloid Malignancies, AML, clinical trials, apoptosis, adult, Translational Research, Clinical Practice (Health Services and Quality), Non-Biological therapies, assays, bioinformatics, Chemotherapy, Combination therapy, Clinical Research, Diseases, patient-reported outcomes, clinical procedures, Therapies, therapy sequence, real-world evidence, Myeloid Malignancies, Biological Processes, survivorship, Technology and Procedures, Study Population, profiling, Human, Minimal Residual Disease , pathogenesis, Animal model, machine learning, molecular testing, omics technologies

295-296 (Ernest N. Morial Convention Center)

Moderators:

Susan DeWolf, MD, Memorial Sloan Kettering Cancer Center and Peter Hokland, DMSc, MD, Aarhus University Hospital

Disclosures:

No relevant conflicts of interest to declare.

2:45 PM

835

Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax

Sari Kytölä, MD¹^*, Ida Vänttinen, MSc²^*, Tanja Ruokoranta, MSc²^*, Annasofia Holopainen, MD³^*, Anu Partanen, MD, PhD³^*, Milla E.L. Kuusisto, MD, PhD^4,5^*, Sirpa Koskela, MD⁶^*, Riikka Räty, MD, PhD¹^*, Maija Itälä-Remes, MD, PhD⁷^*, Amanda Ranta, MSc²^*, Minna Suvela, MSc²^*, Alun Parsons²^*, Imre Västrik, PhD²^*, Sanna M. Siitonen, MD, PhD⁸, Kimmo Porkka, MD, PhD^1,9^*, Krister Wennerberg, PhD¹⁰^*, Caroline A. Heckman, PhD^2,9, Pia Ettala, MD⁷^*, Johanna Rimpiläinen, MD⁶^*, Timo Siitonen, MD, PhD⁴^*, Marja Pyörälä, MD, PhD³^*, Heikki Kuusanmäki, PhD^2,10,11 and Mika Kontro, MD, PhD^1,2,11^*

¹Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
²Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
³Department of Medicine, Kuopio University Hospital, Kuopio, Finland
⁴Department of Medicine, Oulu University Hospital, Oulu, Finland
⁵Department of Hematology, University of Oulu, Oulu, Finland
⁶Department of Internal Medicine, Tampere University Hospital, Tampere, Finland
⁷Department of Clinical Hematology, Turku University Hospital, Turku, Finland
⁸Department of Clinical Chemistry, University of Helsinki and HUSLAB, Helsinki University Central Hospital, Helsinki, Finland
⁹iCAN Digital Precision Cancer Center Medicine Flagship, University of Helsinki, Helsinki, Finland
¹⁰Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark
¹¹Foundation for the Finnish Cancer Institute, Helsinki, Finland

3:00 PM

836

Macs - a Leukemic Stem Cell- Based Predictor of Clinical Response to Venetoclax and Other BH3 Mimetics for Acute Myeloid Leukemia

Simon Renders, MD^1,2,3^*, Alexander Waclawiczek, PhD^1,3^*, Aino-Maija Leppä, MSc^1,3^*, Cecilia Reyneri, M.Sc.^1,3^*, Barbara Betz, B.Sc.^1,3^*, Karolin Stumpf, B.Sc.^1,3^*, Maike Janssen, MD²^*, Julia M. Unglaub, MD²^*, Elisa Donato, PhD^1,3^*, Rabia Shahswar, MD⁴^*, Simon Raffel, MD², Michael Heuser, MD⁴, Richard F. Schlenk, MD^2,5, Michael Hundemer, MD^6,7^*, Tim Sauer, MD²^*, Carsten Müller-Tidow, MD²^* and Andreas Trumpp, PhD^1,3

¹Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM GmBH), Heidelberg, Germany
²Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
³Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany
⁴Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
⁵National Center of Tumor Diseases, Heidelberg, Heidelberg, Germany
⁶MVZ für hämatologische Diagnostik, Heppenheim, Germany
⁷Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany

3:15 PM

837

Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia

Guangyang Weng, MD^1,2^*, Yu Zhang¹^*, Guopan Yu, MD¹^*, Na Xu, MD, PhD¹^*, Zhiqiang Sun, MD, PhD³^*, Dongjun Lin, MD⁴^*, Xinquan Liang⁵^*, Lan Deng, MD, PhD⁶^*, Jie Xiao, MD⁷^*, Hongyu Zhang, MD, PhD⁸, Ziwen Guo, MD⁹^*, Hua Jin¹^*, Xin Du¹⁰^* and Qifa Liu, MD¹¹

¹Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
²Department of Hematology, First Affiliated Hospital of Shenzhen University, The Second People's Hospital of Shenzhen, Shenzhen, China
³Department of Hematology, Shenzhen Hospital, Southern Medical University, shenzhen, China
⁴Department of Hematology, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China
⁵Department of Hematology, First People’s Hospital of Chenzhou, Chenzhou, China
⁶Department of Hematology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
⁷Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
⁸Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China
⁹Department of Hematology, Zhongshan City People’s Hospital, Zhongshan, China
¹⁰Department of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, CA, China
¹¹Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

3:30 PM

838

Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

Jesse M. Tettero^1,2^*, Lok Lam Ngai, MD^1,2^*, Costa Bachas, PhD^1,2^*, Dimitri A. Breems, MD, PhD³, Thomas Fischer, MD⁴, Bjørn Tore Gjertsen, MD, PhD⁵^*, Patrycja Gradowska, MSc⁶^*, Laimonas Griskevicius, MD, PhD⁷^*, Jeroen J.W.M. Janssen, MD, PhD^1,2^*, Gunnar Juliusson, MD, PhD⁸, Johan A. Maertens, MD, PhD⁹^*, Markus G Manz^10,11, Thomas Pabst, MD^11,12, Jakob Passweg, MD^11,13^*, Kimmo Porkka, MD, PhD¹⁴^*, Peter JM Valk, PhD¹⁵, Bob Lowenberg, Prof MD PhD¹⁵, Gert J. Ossenkoppele, MD, PhD^1,2 and Jacqueline Cloos, Prof^1,2^*

¹Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands
²Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, Netherlands
³Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium
⁴Otto von Guericke University Hospital Magdeburg, Magdeburg, Germany
⁵Haukeland University Hospital, Bergen, NOR
⁶Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands
⁷Vilnius University Hospital Santaros Klinikos, Vilnius, Na, Lithuania
⁸Skanes University Hospital, Lund, Sweden
⁹University Hospital Gasthuisberg, Leuven, Belgium
¹⁰University Hospital Zurich, Zurich, Switzerland
¹¹Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
¹²University Hospital Bern, Inselspital, Bern, Switzerland
¹³University Hospital Basel, Basel, CHE
¹⁴Helsinki University Central Hospital Cancer Center, Helsinki, Finland
¹⁵Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands

3:45 PM

839

Prognostic Effect and Clinical Application of Early Measurable Residual Disease (MRD) By Flow Cytometry on De Novo Acute Myeloid Leukemia (AML)

Congxiao Zhang, MD¹^*, Runxia Gu²^*, Chunlin Zhou²^*, Yan Li³^*, Yuntao Liu²^*, Shuning Wei⁴^*, Dong Lin⁵^*, Benfa Gong²^*, Kaiqi Liu²^*, Qiuyun Fang⁴^*, Xiaoyuan Gong, MD⁵^*, Shaowei Qiu, MD^2,6^*, Bingcheng Liu⁵^*, Ying Wang, MD², Hui Wei, MD⁷^*, Yingchang Mi⁵^* and Jianxiang Wang, MD²

¹State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, CA, China
²State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
³Institute of Hematology and Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Tianjin, China
⁴State Key Laboratory of Experimental Hematology. National Clinical Research Center for Blood Diseases. Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
⁵State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China
⁶State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, BIRMINGHAM, AL
⁷State Key laboratory of Experimental Hematolog, National Clinical Research Center for Blood Disease, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

4:00 PM

840

Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy

Jad Othman, MBBS^1,2, Ing S Tiong, FRACP, FRCPA, MPhil^3,4,5, Katya Mokretar⁶^*, Adam Ivey, BSc, MSc, PhD⁷^*, Michael James Austin⁸^*, Anne-Louise Latif⁹^*, Charles Crawley¹⁰, Mariam Amer¹¹^*, Francesca Crolla, MBBChir, MRCP¹²^*, Joe W Cross, PhD, BMBS¹³^*, Raymond Dang¹⁴^*, Chun Yew Fong, MBBS, PhD, FRACP, FRCPA¹⁵, Sofia Galli¹⁶^*, Paolo Gallipoli, MD⁸, Francesca L Hogan¹⁷^*, Pallavi Kalkur, MBBS, MRCP, FRCPath¹⁸^*, Anjum Khan¹⁹^*, Pramila Krishnamurthy, MD²⁰^*, John Laurie, MB ChB²¹^*, Scott R. Marshall, BSc, MD, PhD²²^*, Vidhya Murthy, MRCP²³^*, Sateesh K. Nagumantry²⁴^*, Srinivas Pillai, MBBS, MD, MRCP, FRCPath²⁵^*, Nicola Potter, PhD²^*, Tom Taylor²⁶^*, Rui Zhao, MBBS, PhD, MRCP, FRCPath²⁷, Andrew H Wei, MBBS, PhD²⁸ and Richard Dillon, MA PhD MRCP FRCPath^1,29

¹Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
²Department of Medical and Molecular Genetics, King's College London, London, United Kingdom
³The Alfred Hospital and Monash University, Melbourne, VIC, Australia
⁴Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, Melbourne, VIC, Australia
⁵Austin Health and Olivia Newton John Cancer Research Institute, Melbourne, Australia
⁶Cancer Genetics, Viapath, London, ENG, GBR
⁷Molecular Pathology, The Alfred Hospital, Melbourne, VIC, Australia
⁸Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
⁹Department of Haematology, Queen Elizabeth University Hospital, Glasgow, United Kingdom
¹⁰Addenbrooke's Hospital, Cambridge, GBR
¹¹University Hospital Southampton, Southampton, United Kingdom
¹²Musgrove Park Hospital, Taunton, ENG, GBR
¹³University Hospital Bristol, Bristol, ENG, GBR
¹⁴James Cook University Hospital, Middlesbrough, GBR
¹⁵Austin Health and Olivia Newton John Cancer Research Institute, Melbourne, VIC, Australia
¹⁶Frimley Park Hospital, London, GBR
¹⁷University Hospital of Wales, Cardiff, GBR
¹⁸Southend Hospital, Southend, GBR
¹⁹St James's Institute of Oncology, The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
²⁰King’s College Hospital, London, United Kingdom
²¹Worthing Hospital, Worthing, United Kingdom
²²City Hospitals Sunderland NHS Trust, Sunderland, GBR
²³Centre for Clinical Haematology, University Hospitals Birmingham, Birmingham, United Kingdom
²⁴Peterborough City Hospital, Peterborough, United Kingdom
²⁵Royal Stoke University Hospital, University Hospital of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom
²⁶Nottingham University Hospital, Nottingham, United Kingdom
²⁷Torbay Hosital, Torquay, GBR
²⁸Department of Clinical Haematology, Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, Melbourne, VIC, Australia
²⁹Department of Medical and Molecular Genetics, King's College London, London, ENG, United Kingdom

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

617.O1.6 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Venetoclax, HMA, and Response to Treatment in AML